Celgene (CELG) Tops Q4 EPS by 2c, Offers FY17 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts CELG Hot Sheet
Price: $108.24 --0%
Financial Fact:
Research and development: 1.65B
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Research and development: 1.65B
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Celgene (NASDAQ: CELG) reported Q4 EPS of $1.61, $0.02 better than the analyst estimate of $1.59. Revenue for the quarter came in at $2.98 billion versus the consensus estimate of $3.02 billion.
GUIDANCE:
Celgene sees FY2017 EPS of $7.10-$7.25, versus the consensus of $7.13. Celgene sees FY2017 revenue of $13-13.4 billion, versus the consensus of $13.3 billion.
For earnings history and earnings-related data on Celgene (CELG) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Datadog, Inc. (DDOG) Tops Q3 EPS by 17c, Offers Guidance
- Harmony Biosciences (HRMY) Misses Q3 EPS by 30c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
